Strategic partnerships Leverage Entero Therapeutics' focus on targeted, non-systemic GI therapies and its two proprietary technologies (niclosamide and adrulipase) to pursue collaborations with contract research organizations, GI disease specialty clinics, and large pharma seeking novel GI treatment modalities.

Clinical-stage opportunities Target late-stage clinical opportunities and potential licensing deals around latiglutenase for celiac disease and adrulipase for exocrine pancreatic insufficiency, aligning with CROs and patient advocacy groups to accelerate recruitment and market readiness.

AI and data center synergies Capitalize on Entero’s recent Grid AI Corp launch and acquisition to offer joint solutions that couple GI therapeutic data analytics with AI-driven infrastructure, appealing to healthcare tech partners, data services vendors, and biopharma R&D teams seeking digital health-enabled trials.

Financially opportunistic timing Engage investors and strategic buyers by aligning financing milestones with key clinical milestones and potential product approvals, highlighting the company’s $79M funding runway and recent financing activities to support co-development and go-to-market planning.

Global commercialization prep Prepare a market-entry play targeting gastroenterology centers and payer discussions in regions with high celiac and GI disease prevalence, leveraging existing clinical operations in California and Boca Raton to pilot regional launches and create evidence for reimbursement negotiations.